Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05049837 · ClinicalTrials.gov registry record
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
A clinical trial of Lung Cancer and Cancer of Thorax, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 7,200
- Enrollment target
- 1
- Study location
NCT05049837 is a study of Lung Cancer and Cancer of Thorax that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 7,200 participants, above the 918-participant average among 409 other Lung Cancer trials with a reported enrollment target (684% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05049837, a study of Lung Cancer and Cancer of Thorax, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 7,200 participants
- Enrollment target
- 1
- Study location
Study Summary
In this Project, we will use therapeutic target -focused (TTF) profiling, genome-wide mRNA profiling and assessments of tumor phosphopeptides and DNA that are shed into the blood stream to define how various molecular factors alone and in combination relate to resistance to therapy, to prognosis, and to metastatic patterns at relapse. We will examine how the presence of factors that drive cell growth, antagonize apoptosis, or confer resistance in other ways may counter the effect of systemic therapies and/or promote rapid tumor recurrence. In this way, we will identify new, previously unappreciated potential therapeutic targets while also identifying which targets are most likely to increase resistance to therapy and worsen prognosis.
Conditions Studied
Interventions
- OTHER Group Specific Aim 1
- OTHER Group Specific Aim 2
- OTHER Group Specific Aim 3
- OTHER Group Specific Aim 4
- OTHER Group Specific Aim 5
Study Locations (1)
Texas
- M D Anderson Caner Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,200 participants |
| Start Date | 2007-04-25 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05049837
The ClinicalTrials.gov registry entry for NCT05049837 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 7,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 918-participant average among 409 other Lung Cancer trials with a reported enrollment target (684% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Group Specific Aim 1 is the first listed.
NCT05049837 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05049837 about?
NCT05049837 is a clinical study titled "PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification". In this Project, we will use therapeutic target -focused (TTF) profiling, genome-wide mRNA profiling and assessments of tumor phosphopeptides and DNA that are shed into the blood stream to define how various molecular factors alone and in combination relate to resistance to therapy, to prognosis, an...
What is the current status of trial NCT05049837?
This trial is currently recruiting. The enrollment target is 7,200 participants. The study started on 2007-04-25. Estimated completion is 2025-12-31.
What conditions does trial NCT05049837 study?
This clinical trial studies the following conditions: Lung Cancer, Cancer of Thorax.
What interventions are being tested in trial NCT05049837?
The interventions under investigation include: Group Specific Aim 1 (OTHER), Group Specific Aim 2 (OTHER), Group Specific Aim 3 (OTHER), Group Specific Aim 4 (OTHER), Group Specific Aim 5 (OTHER).
Who is sponsoring clinical trial NCT05049837?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05049837 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.